23S rRNA Inhibitors
4 drugsAbout 23S rRNA
The 23S rRNA is a crucial component of the bacterial ribosome, responsible for protein synthesis. Disrupting its function halts bacterial protein production, leading to cell death or growth inhibition, making it a valuable antibacterial target.
The demonstrated efficacy of drugs targeting 23S rRNA underscores its importance as a therapeutic target. Currently, there is no genetic evidence directly linking variations in 23S rRNA sequence to specific disease states.
Four small molecule drugs, including CLEOCIN, LINCOCIN, and their formulations, target 23S rRNA. These drugs, developed by Pfizer, were approved between 1964 and 1980 for various bacterial infections.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Non-Small-Cell Lung with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top 23S rRNA Drugs
Pfizer is the only company with approved drugs targeting 23S rRNA.
High market concentration indicates potential entry barriers, requiring strong IP or novel mechanisms.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| CLEOCIN | PHARMACIA AND UPJOHN | 1980 | 1 |
23S rRNA Drug Modality Landscape
Modalities
Routes of Administration
23S rRNA is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like oligonucleotides or peptides to differentiate from existing therapies.
23S rRNA Clinical Trials 49 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 8 | 1 | 0 | 89% |
| Phase 2 | 9 | 4 | 1 | 4 | 80% |
| Phase 3 | 12 | 12 | 0 | 0 | 100% |
| Phase 4 | 19 | 11 | 0 | 8 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
23S rRNA Drug Approval Timeline (1970 - 1972)
The first drug targeting 23S rRNA was approved in 1964, and the most recent in 1980.
The long gap since the last approval suggests saturation or challenges in developing new 23S rRNA-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 34 clinical trials targeting 23S rRNA.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities